Participation Studies

This page provides people living with mental illness, their families, and mental health researchers with an opportunity to connect in mental health research studies.

NAMI-NYC Metro does not endorse any study on this page. Information is provided purely as a public service.

A group wishing to post on this page must submit their current IRB approval for the study, in addition to a written synopsis of your study answering the following:

  • A title
  • A brief description of the study.
  • Is the study therapeutic (offering treatment) or non-therapeutic?
  • Is the study funded? If yes, provide source of all funding; e.g., non-profit organization, governmental agency, or for-profit corporation including any ties to the pharmaceutical industry.
  • Who will be conducting the study? E.g. non-profit, government, hospital, or for-profit corporation, including any companies that run clinical trials.
  • Will subjects be paid? Include payment schedule and amount.

Current Studies

May 2017: Schizophrenia & Bipolar Research Study

We are looking for young adults 18-30 years old who have been diagnosed with schizophrenia, schizoaffective disorder, or bipolar disorder. You may be eligible to participate in a MRI research study that aims to understand the biology of schizophrenia disorder and bipolar disorder and their relation to cognition. We’re also looking for siblings.

  • Young adults (18-30 years old) with a diagnosis of schizophrenia or schizoaffective disorder.
  • Young adults (18-30 years old) with a diagnosis of bipolar disorder who have also had the experience of hearing or seeing things that other can’t, or having beliefs that others don’t agree with.
  • The sibling of a young adult who has been diagnosed with schizophrenia, schizoaffective disorder, or bipolar disorder and who has also had the experience of hearing or seeing things that other can’t, or having beliefs that others don’t agree with.

The study involves no treatment or modification of current treatment.

You will be compensated for your participation in the study.

If you are interested in participating please contact our coordinator at: cbibrainlab@nyumc.org or 212-263-3945 for more information.

April 2017: Clinical trial of a drug called Rapastinel

Are you currently taking a medication but still feeling depressed?

If you’re 18-65 years old, have been diagnosed with Major Depressive Disorder, and are experiencing the symptoms below, you may be eligible to participate in a clinical research study of an investigational product. All study related drug and visits will be provided to you at no cost.

Hopelessness, sadness, loss of interest, decreased energy, difficulty concentrating.

Our team at Fieve Clinical Research is currently recruiting patients for a randomized, double-blind, phase-III clinical trial of a drug called Rapastinel. The investigational product (IP) is being tested for safety and efficacy as an adjunctive therapy for treatment-resistant depression. The trial includes 12 visits over a six-week period, with a three-week dosing period where the subject will receive either 450 mg of the study drug administered via IV, or will receive a placebo. Participants will remain on their current antidepressant treatment during the trial. Eligible participants must be between the ages of 18-65, not responding to their current FDA-approved antidepressant treatment, and be currently depressed.

Subjects will be compensated $50 per study visit, for a total of $600 if all visits are completed.

Call (212) 772-3570.

April 2017: Clinical Research Study -- Investigational Medicinal Product for Major Depression

If your child is affected by depression and still experiencing its symptoms – you may be interested in the Kites study. Kites is an international clinical research study that is looking at the safety and effectiveness of an investigational medicinal product for major depression in children and adolescents.

The Kites study team is looking for young people who are:

  • aged between 7 and 17
  • diagnosed with major depressive disorder (MDD)
  • being treated for depression as an outpatient
  • available to take part in the study for up to 16 weeks

If your child meets these criteria and you would like to find out more about the Kites study, please go to www.kites-study.com or contact Walid Elsharkawi at walidelsharkawi.mbm@gmail.com or Marie Grant at mariegrant.mbm@gmail.com for more information. They can also be reached via phone at 646-678-4196.

September 2016: The Role of Dysmyelination in Cognitive Impairment of Psychotic Spectrum Disorders

New York University School of Medicine: Brain Imaging Study

We are recruiting 18-30 year old participants who have been diagnosed with schizophrenia or bipolar disorder with psychosis in the last five years. An initial telephone screening and clinical interview will establish eligibility for the study.

The primary objective of this study is to understand how brain anatomy relates to function and health. This study is funded by the National Institute of Mental Health and is conducted at New York University School of Medicine, Department of Radiology.

The study involves:

  • Clinical assessment
  • MR scanning
  • Blood draw
  • Cognitive Assessment

This is a non-therapeutic study that does not involve treatment and does not interfere with any ongoing treatments.

If eligibility criteria are met, a compensation of $160 will be provided for the completion of the study. For more information please contact Mariana Lazar at mariana.lazar@nyumc.org or 212-263-3348.

August 2016: Genomic Psychiatry Cohort Study: Schizophrenia, Bipolar Disorder

We are currently seeking individuals 18 years or older diagnosed with schizophrenia or bipolar disorder to take part in a genetics study at NYU School of Medicine. The study’s purpose is to investigate the genetic risks associated with these chronic mental illnesses.

The study involves a brief screening questionnaire, a diagnostic interview, two short questionnaires asking about your history of trauma and aggression, and a blood draw of no more than 4 tablespoons. The study should take 2-3 hours to complete and you will be compensated $50 in cash.

If you are interested in participating, please contact Mara at Inspiresresearch@gmail.com or by phone at (646) 754-4817 between the hours of 9:30am-5pm MondayFriday.

March 2016: Intravenous Sodium Nitroprusside in Adults with Symptomatic Schizophrenia

NYU Langone Medical Center – Schizophrenia Research Lab

The purpose of this study is to find out if sodium nitroprusside, when given intravenously (into a vein) can help reduce various symptoms of schizophrenia, compared to a placebo. Current treatments for schizophrenia may require weeks to produce a therapeutic effect, and other efforts to find better-tolerated treatments have not met much success.

Eligibility:

  • 18-60 years old
  • Diagnosis of schizophrenia
  • Currently treated with an antipsychotic

Compensation:

  • Study involves 9 visits (2 infusions)
  • Up to $840.00 for participation

For more information, please contact:
Erica Diminich, PhD
Erica.Diminich@nyumc.org
646-754-4803

January 2016: Rutgers University Research Study: Tele-Psychiatry Intervention to Improve Engagement in, and Outcomes from, Family Psychoeducation for Serious Mental Illness

Seeking Caregivers for Individuals Diagnosed with Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder

We are currently recruiting for a study of the effects of various family support programs for those who are the primary caregiver for someone diagnosed with a serious mental illness.

Eligibility:

  • Residing in the New Jersey, New York, or Philadelphia area
  • Access to computer or tablet with internet
  • Participants and their loved ones must be over the age of 18 and be in contact with each other 2-3x per week or living together

Compensation:

  • Study involves 3 phone interview appointments
  • Participants receive $10 per phone appointment

For more information or to sign up as a participant, please contact our research assistant:
Victoria Martin
Rutgers UBHC
151 Centennial Avenue
Piscataway NJ 08854
Tel: 732-235-5098
vm367@ubhc.rutgers.edu

December 2015: Ketamine Plus Lithium as a Novel Pharmacotherapeutic Strategy in Treatment-Resistant Depression

Icahn School of Medicine at Mount Sinai

The purpose of this study is to test the antidepressant effect of ketamine when given repeatedly over a period of 1 week, as well as the use of Lithium as a relapse-prevention strategy for patients with treatment-resistant depression (TRD) who respond to an initial ketamine infusion. An additional purpose of this study is to research the effects of ketamine on brain function.

Compensation per each visit listed below:

  • Screening (including medical clearance): $50
  • Ketamine infusion (1 visit): $60
  • 24 hour follow-up visit/lithium randomization visit: $20
  • Baseline fMRI: $200
  • Continuation ketamine Infusions (3 visits): $180
  • fMRI scan following first infusion: $200
  • Weekly clinic visits (up to 6): $120
  • fMRI scan 2 weeks following last infusion: $100
  • Total for completion of all phases of the study: $930

For more information, please contact:

Jaclyn Schwartz, Jaclyn.schwartz@mssm.edu, 212-241-3116

December 2015: Cognitive Training for Mood and Anxiety Disorders

Icahn School of Medicine at Mount Sinai

The primary objective is to investigate the efficacy of a novel cognitive training computer program in treating depression and anxiety. The training program seeks to improve working memory and attention in addition to alleviating depressive and anxious symptoms.

Compensation per each visit listed below:

  • Screening visit 1 (initial interview): $25
  • Baseline assessment: $50
  • Weekly clinician check-ins (5 x $20 each): $100
  • Mid-study assessment (including week 3 check-in): $40
  • Final assessment: $50
  • Total for participation in all parts of the study: $265

For more information, please contact:

Megan Hoch: megan.hoch@mssm.edu, 212-241-3089

December 2015: Randomized Controlled Trial of Repeated Dose Intravenous Ketamine for PTSD

Icahn School of Medicine at Mount Sinai

The purpose of this study is to study new ways to treat post-traumatic stress disorder (PTSD). Current treatments for PTSD do not work for everyone and it can take time to determine whether a person responds to a chosen treatment. The purpose of this study is to see whether ketamine, when given repeatedly intravenously (into a vein) can produce a quick and persistent improvement in PTSD symptoms, compared to the active control of midazolam.

Compensation per each visit listed below:

  • Screening: $75
  • First MRI scan (Friday before first administration): $100
  • Visit 1a (Monday of first administration): $75
  • Visit 1b (24 hour): $50
  • Second MRI scan (also 24 hour): $100
  • Visit 2 (Second administration): $50
  • Visit 3 (Third administration): $50
  • Week Two administrations (visits 4-6): $175
  • Visit 7 (exit): $50
  • Study Visits Total, including two scans: $725
  • Follow-up phase (*weekly for one month, monthly for 6 months): $25/visit

For more information, please contact:

Sarah Horn: sarah.horn@mssm.edu, 212-241-7910

September 2015: D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions

NYU Langone Medical Center – Schizophrenia Research Lab.

Have you been diagnosed with Schizophrenia, Schizoaffective or Delusional Disorder?

We are looking for volunteers between the ages of 18-68 years old interested in participating a weekly research study.

Up to $400.00 in compensation for participation.

Brief Summary

The purpose of this study is to investigate if D-cycloserine (DCS) along with once-weekly CBT sessions can help individuals with treatment-resistant delusions. This study aims to help increase mental flexibility and memory for information learned during CBT sessions.

Learn more about the study here.

For more information, please contact:
Erica Diminch Ph.D
Erica.Dimich@nyumc.org
646-754-4803

June 2015: Psychosis Biomarker Study

Columbia University Child Psychiatry Dept.

The Columbia University Child Psychiatry Department is conducting a psychosis biomarker study, investigating the underlying causes of psychosis, specifically immune and infectious causes. We are recruiting those ages 8-35 who have experienced psychosis, as well as unaffected siblings of those with psychosis. The study involves an approximate 2 hour clinical assessment and requires a blood draw and a urine sample.

Participant Eligibility criteria includes:

  • Ages 8-35
  • Experienced psychosis in the past or currently
  • Also recruiting unaffected siblings of those with psychosis, ages 8-35

Study participants will receive a cash stipend of $25.

For more information, please contact:
Shannon Delaney, MD
sld2158@cumc.columbia.edu. (Please include “Psychosis Biomarker Study” in the subject line.)
347-560-9006